bioRxivMicrobiology
Refinement of metabolite detection in cystic fibrosis sputum reveals heme negatively correlates with lung function
N. R. Glasser, R. C. Hunter, T. G. Liou, D. K. K. Newman, Mountain West CF Consortium Investigators
Abstract
Pseudomonas aeruginosa lung infections are a leading cause of morbidity and mortality in cystic fibrosis (CF) patients (1, 2). Our laboratory has studied a class of small molecules produced by P. aeruginosa known as phenazines, including pyocyanin and its biogenic precursor phenazine-1-carboxylic acid (PCA). As phenazines are known virulence factors (3), we and others have explored the possibility of using phenazine concentrations as a marker for disease progression (4-6). Previously, we reported that sputum concentrations of pyocyanin and PCA negatively correlate with lung function in cystic fibrosis patients (6). Our study used high performance liquid chromatography (HPLC) to quantify phenazines by UV-vis absorbance after extraction from lung sputum. Since our initial study, methods for metabolite analysis have advanced considerably, aided in large part by usage of mass spectrometry (LC-MS) and tandem mass spectrometry (LC-MS/MS). Because a more recent study employing LC-MS/MS revealed a surprising decoupling of P. aeruginosa metabolites in sputum and the detection of P. aeruginosa through culturing or microbiome profiles (4), we decided to check whether we could reproduce our previous findings by analyzing sputum samples from a different patient cohort with a new LC-MS instrument in our laboratory. Our new samples were provided by the Mountain West CF Consortium Sputum Biomarker study (7). In the course of performing our new analyses, comparison of our old HPLC data to our new LC-MS data led us to realize that the peak previously assigned to PCA instead originates from heme, and the peak assigned to pyocyanin originates from an as-yet unknown compound. This correction only affects the measurements of phenazines in sputum, and we are confident in the phenazine measurements from isolated cultures and the 16S rRNA gene sequencing data from that study (6). Here we outline the basis for our correction and present additional data showing that heme concentration negatively correlates with lung function in cystic fibrosis patients.
- organism: human
- assay: metabolomics
- research focus: differential expression
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- PSEUDOMONAS AERUGINOSA VOLATILOME CHARACTERISTICS AND ADAPTATIONS IN CHRONIC CYSTIC FIBROSIS LUNG INFECTIONS
T. J. Davis, A. V. Karanjia, … H. D. Bean·bioRxiv·Jun 13, 2020
- Analysis of Pseudomonas aeruginosa transcription in an ex vivo cystic fibrosis sputum model identifies metal restriction as a gene expression stimulus
S. L. Neff, G. Doing, … D. A. Hogan·bioRxiv·Aug 21, 2023
- Sputum Proteomics reveals unique signatures linked to key outcomes in cystic fibrosis trials.
Sian Pottenger, Dilip S. Nazareth, … Joanne L. Fothergill·bioRxiv·Jul 23, 2024
- Microbiome data enhances predictive models of lung function in people with cystic fibrosis
Conan Zhao, Yi‐Qi Hao, … Sam P. Brown·The Journal of Infectious DiseasesPeer-reviewed·Oct 14, 2020
- Differential Metabolite Production Underlies Disruption of the Cystic Fibrosis Airway Microbiota by Pathogens
Sydney M. Morabbi, Niladri Bhowmik, … Reed M. Stubbendieck·bioRxiv·Jul 17, 2026
- Taxonomic variability over functional stability in the microbiome of Cystic Fibrosis patients chronically infected by Pseudomonas aeruginosa
G. Bacci, G. Taccetti, … A. Bevivino·bioRxiv·Jan 27, 2020